Expression and Role of the JAK/STAT Pathway in Sarcoidosis Granuloma Cells

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Feb 10, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating the role of a specific signaling pathway called JAK/STAT in cells involved in sarcoidosis, a condition that causes inflammation and can affect different organs, especially the lungs. Researchers believe that understanding this pathway could help identify the best treatments for patients with severe sarcoidosis who haven't responded well to other therapies. The trial is currently looking for participants, including both men and women aged 18 to 75, who have been diagnosed with or are suspected to have a type of sarcoidosis affecting the lungs.

To join the study, participants need to have had a recent chest CT scan and meet certain criteria set by medical guidelines. Those who are pregnant or do not wish to participate will be excluded. If you decide to take part, you can expect to contribute to important research that may lead to better treatment options for sarcoidosis. This trial aims to gather valuable information that could help tailor therapies for patients facing challenges with their condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a diagnosis of mediastinopulmonary sarcoidosis made according to ATS / ERS / WASOG criteria
• • Or patient suspected of having mediastino-pulmonary sarcoidosis, without any other probable causal factor identified on the usual standard examination at the time of the sample with the need for diagnostic confirmation at the end of the study according to the criteria of the ATS / ERS / WASOG
• • Sarcoidosis with stage 1 to 4 pulmonary involvement
• • Patients who had a chest CT scan in the 6 months preceding the sample. Examination carried out as part of routine care
• Exclusion Criteria:
• • Pregnancy.
• • Opposition expressed to participation in the study.
• • Patients on State Medical Aid.